Ionis Pharmaceuticals (IONS)

Company Description

Ionis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. The company’s broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. IONS’ partner, Genzyme, plans to commercialize its lead product, Kynamro, in the U.S. and Europe following regulatory approval. IONS’ patents provide strong and extensive protection for its drugs and technology.

COMPANY ADDRESS
2855 Gazelle Court
Carlsbad, CA 92010
United States

COMPANY PHONE
760-931-9200

COMPANY WEBSITE



Get BioInvest's perspective on Ionis Pharmaceutical's CEO


Latest Company News

The Ionis Pharmaceuticals Inc. (IONS) Given a $61.00 Price Target by the BMO ... DailyQuint - 40 minutes ago Ionis Pharmaceuticals logo Ionis Pharmaceuticals Inc. (NASDAQ:IONS) received a $61.00 target price from analysts at BMO Capital Markets in a note issued to investors on Tuesday. [...]
Wed, Feb 22, 2017 12:46:00 PM, Continue reading at the source
Blog Coverage Ionis Pharma Closed on its Collaboration Agreement with Novartis ... Yahoo Finance - Feb 17, 2017 On February 16, 2017, Ionis Pharma and Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., announced that they have closed on their exclusive, worldwide option and collaboration agreement with Novartis to develop and ... As Isis Pharmaceuticals, Inc. Trades Do Analysts Recommend You Sell? - The De Soto Edge [...]
Fri, Feb 17, 2017 1:30:00 PM, Continue reading at the source
Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical ... PR Newswire (press release) - Feb 16, 2017 CARLSBAD, Calif. and CAMBRIDGE, Mass., Feb. 16, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., announced today they have closed on their exclusive ... [...]
Thu, Feb 16, 2017 12:00:00 PM, Continue reading at the source
Ionis Pharmaceuticals to Hold 2016 Financial Results Conference Call PR Newswire (press release) - Feb 15, 2017 CARLSBAD, Calif., Feb. 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, February 28 at 11:30 a.m. Stock Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc Earns $75 Million from ... - Smarter Analyst Ionis Pharmaceuticals, Inc. (IONS) Rating Increased to Buy at Zacks Investment ... - The Cerbat Gem [...]
Wed, Feb 15, 2017 12:00:00 PM, Continue reading at the source
Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a New ... PR Newswire (press release) - Feb 2, 2017 CARLSBAD, Calif., Feb. 2, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it has earned a $5 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. [...]
Thu, Feb 02, 2017 12:00:00 PM, Continue reading at the source
5 Slides Every Ionis Pharmaceuticals Inc Investor Needs to See Motley Fool - Jan 5, 2017 Ionis Pharmaceuticals (NASDAQ:IONS) gave investors an update on its pipeline today with a slide deck that contained a whopping 65 entries. Jefferies Reiterates a Sell Rating on Ionis Pharmaceuticals Inc - Analyst Ratings Ionis Pharmaceuticals, Inc. (IONS) SVP Brett P. Monia Sells 309 Shares - Sports Perspectives [...]
Thu, Jan 05, 2017 9:45:00 PM, Continue reading at the source
Better Buy: Ionis Pharmaceuticals, Inc. vs. Bellicum Pharmaceuticals Motley Fool - Dec 12, 2016 Most companies the size of Ionis Pharmaceuticals would be thrilled with two candidates like volanesorsen and Spinraza, but there's plenty more coming through the pipe. [...]
Mon, Dec 12, 2016 2:37:00 PM, Continue reading at the source
4 Factors That Catapulted Ionis Pharmaceuticals Inc. 68% Higher in November Motley Fool - Dec 4, 2016 Shares of Ionis Pharmaceuticals (NASDAQ:IONS), a biopharmaceutical company that utilizes its proprietary antisense drug development platform to combat a host of ailments ranging from cancer to rare diseases, catapulted higher by 68% in November, ... [...]
Sun, Dec 04, 2016 6:24:00 PM, Continue reading at the source
3 Potentially Huge Catalysts for Ionis Pharmaceuticals, Inc. in 2017 Motley Fool - Nov 23, 2016 To say that 2016 has been an up-and-down year for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is an understatement. In the first half of the year, shares of the biotech plunged more than 60%. [...]
Wed, Nov 23, 2016 9:22:00 PM, Continue reading at the source
Why Ionis Pharmaceuticals Inc. Skyrocketed Higher Today Motley Fool - Nov 7, 2016 Ionis Pharmaceuticals (NASDAQ:IONS) is up 20.8% at noon EST, after announcing with its partner Biogen (NASDAQ:BIIB) that their spinal muscular atrophy (SMA) drug nusinersen, which now goes by the branded name Spinraza, passed another phase 3 ... Ionis Bids For Broad Nusinersen Label - Seeking Alpha Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary ... - Business Wire (press release) [...]
Mon, Nov 07, 2016 5:50:00 PM, Continue reading at the source